Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06308926
PHASE2

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Sponsor: MedRegen LLC

View on ClinicalTrials.gov

Summary

This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.

Official title: A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress Syndrome

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-12-01

Completion Date

2026-07-01

Last Updated

2024-08-23

Healthy Volunteers

No

Interventions

DRUG

MRG-001 (Low-dose)

MRG-001 is subcutaneously administered.

DRUG

MRG-001 (High-dose)

MRG-001 is subcutaneously administered.

OTHER

Placebo

Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.